Top

Current Pulmonology Reports

Published in:

01-12-2019 | Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease (A Hajari Case, Section Editor)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Who to Treat, How to Treat

Authors: Tejaswini Kulkarni, Steven R. Duncan

Published in: Current Pulmonology Reports | Issue 4/2019

Abstract

Purpose of Review

Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are the most frequent cause of death among patients with IPF. Here, we review the revised definition and diagnostic criteria for AE-IPF and discuss management strategies including mechanistically targeted investigational therapies for this complex syndrome.

Recent Findings

Novel therapies targeting various pathways including inflammation, autoimmunity, and coagulation cascade involved in AE-IPF have recently been reported. Although most of these reports are small and uncontrolled, they have provided evidence to design larger randomized, controlled, multicenter studies to improve outcomes among patients with AE-IPF.

Summary

AE-IPF has a dismal prognosis and current treatment consists mainly of supportive care and symptom palliation. There is a lack of consensus on current therapies for AE-IPF, including corticosteroids, but current randomized control studies for newer therapeutic strategies may hold promise.

•• Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. American journal of respiratory and critical care medicine. 2011;183(6):788–824. https://doi.org/10.1164/rccm.2009-040GLOfficial guidelines for diagnosis and management of idiopathic pulmonary fibrosis. CrossRefPubMedPubMedCentral

Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine. 2011;183(4):431–40. https://doi.org/10.1164/rccm.201006-0894CI.CrossRefPubMed

Ryerson CJ, Cottin V, Brown KK, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J. 2015;46(2):512–20. https://doi.org/10.1183/13993003.00419-2015.CrossRefPubMed

•• Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report. American journal of respiratory and critical care medicine. 2016;194(3):265–75. https://doi.org/10.1164/rccm.201604-0801CIOfficial guidelines for diagnosis and management of acute exacerbation of idiopathic pulmonary fibrosis. CrossRefPubMed

Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network I. Acute exacerbations of idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine. 2007;176(7):636–43. https://doi.org/10.1164/rccm.200703-463PP.CrossRefPubMedPubMedCentral

Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, investigators IP. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73. https://doi.org/10.1186/1465-9921-14-73.CrossRefPubMedPubMedCentral

Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190(7):773–9. https://doi.org/10.1164/rccm.201403-0566OC.CrossRefPubMed

• Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. 2017;49(5). https://doi.org/10.1183/13993003.01339-2016Incidence of AE-IPF in a large randomized, controlled double-blind study.CrossRef

Andrade J, Schwarz M, Collard HR, Gentry-Bumpass T, Colby T, Lynch D, et al. The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes. Chest. 2015;148(4):1034–42. https://doi.org/10.1378/chest.14-2889.CrossRefPubMedPubMedCentral

10.

Nikaido T, Tanino Y, Wang X, Sato Y, Togawa R, Kikuchi M, et al. Serum decorin is a potential prognostic biomarker in patients with acute exacerbation of idiopathic pulmonary fibrosis. J Thorac Dis. 2018;10(9):5346–58. https://doi.org/10.21037/jtd.2018.08.60.CrossRefPubMedPubMedCentral

11.

Murata K, Koga Y, Kasahara N, Hachisu Y, Nunomura S, Nakajima N, et al. Accumulation of periostin in acute exacerbation of familial idiopathic pulmonary fibrosis. J Thorac Dis. 2018;10(7):E587–E91. https://doi.org/10.21037/jtd.2018.06.96.CrossRefPubMedPubMedCentral

12.

Enomoto N, Oyama Y, Enomoto Y, Mikamo M, Karayama M, Hozumi H, et al. Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis. Clin Respir J. 2018;12(8):2378–89. https://doi.org/10.1111/crj.12918.CrossRefPubMed

13.

Kakugawa T, Yokota S, Ishimatsu Y, Hayashi T, Nakashima S, Hara S, et al. Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis. Cell Stress Chaperones. 2013;18(5):581–90. https://doi.org/10.1007/s12192-013-0411-5.CrossRefPubMedPubMedCentral

14.

Cao M, Swigris JJ, Wang X, Cao M, Qiu Y, Huang M, et al. Plasma leptin is elevated in acute exacerbation of idiopathic pulmonary fibrosis. Mediators Inflamm. 2016;2016:6940480. https://doi.org/10.1155/2016/6940480.CrossRefPubMedPubMedCentral

15.

Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356–63. https://doi.org/10.1183/09031936.00159709.CrossRefPubMed

16.

Kishaba T, Tamaki H, Shimaoka Y, Fukuyama H, Yamashiro S. Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis. Lung. 2014;192(1):141–9. https://doi.org/10.1007/s00408-013-9530-0.CrossRefPubMed

17.

Simon-Blancal V, Freynet O, Nunes H, Bouvry D, Naggara N, Brillet PY, et al. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration. 2012;83(1):28–35. https://doi.org/10.1159/000329891.CrossRefPubMed

18.

• Paterniti MO, Bi Y, Rekic D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2017;14(9):1395–402. https://doi.org/10.1513/AnnalsATS.201606-458OCPredictors of mortality and morbidity in IPF. CrossRefPubMed

19.

Kondoh Y, Taniguchi H, Katsuta T, Kataoka K, Kimura T, Nishiyama O, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):103–10.PubMed

20.

•• Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82. https://doi.org/10.1056/NEJMoa1402584Landmark trial reporting the benefit of nintedanib in IPF. CrossRefPubMed

21.

•• King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92. https://doi.org/10.1056/NEJMoa1402582 Landmark trial reporting the benefit of pirfenidone in IPF. CrossRefPubMed

22.

Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87. https://doi.org/10.1056/NEJMoa1103690.CrossRefPubMed

23.

Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–7. https://doi.org/10.1164/rccm.200404-571OC.CrossRefPubMed

24.

Lee JS, Song JW, Wolters PJ, Elicker BM, King TE Jr, Kim DS, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012;39(2):352–8. https://doi.org/10.1183/09031936.00050911.CrossRefPubMed

25.

Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369–76. https://doi.org/10.1016/S2213-2600(13)70105-X.CrossRefPubMedPubMedCentral

26.

Weng D, Chen XQ, Qiu H, Zhang Y, Li QH, Zhao MM, et al. The role of infection in acute exacerbation of idiopathic pulmonary fibrosis. Mediators Inflamm. 2019;2019:5160694. https://doi.org/10.1155/2019/5160694.CrossRefPubMedPubMedCentral

27.

Raj R, Raparia K, Lynch DA, Brown KK. Surgical lung biopsy for interstitial lung diseases. Chest. 2017;151(5):1131–40. https://doi.org/10.1016/j.chest.2016.06.019.CrossRefPubMed

28.

Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB. In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011. Am J Respir Crit Care Med. 2016;193(10):1161–7. https://doi.org/10.1164/rccm.201508-1632OC.CrossRefPubMed

29.

Casoni GL, Tomassetti S, Cavazza A, Colby TV, Dubini A, Ryu JH, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One. 2014;9(2):e86716. https://doi.org/10.1371/journal.pone.0086716.CrossRefPubMedPubMedCentral

30.

• Patel NM, Kulkarni T, Dilling D, Scholand MB. Interstitial, diffuse lung disease network steering c. preoperative evaluation of patients with interstitial lung disease. Chest. 2019. https://doi.org/10.1016/j.chest.2019.05.028Pre-, peri- and post-operative risk-reduction in patients with IPF. CrossRef

31.

Choi SM, Lee J, Park YS, Cho YJ, Lee CH, Lee SM, et al. Postoperative pulmonary complications after surgery in patients with interstitial lung disease. Respiration. 2014;87(4):287–93. https://doi.org/10.1159/000357046.CrossRefPubMed

32.

Takao S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, et al. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery. Medicine (Baltimore). 2019;98(5):e14296. https://doi.org/10.1097/MD.0000000000014296.CrossRefPubMedPubMedCentral

33.

Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS(R) trials. Respir Res. 2019;20(1):71. https://doi.org/10.1186/s12931-019-1037-7.CrossRefPubMedPubMedCentral

34.

Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD. Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization. Respir Med. 2015;109(12):1582–8. https://doi.org/10.1016/j.rmed.2015.11.001.CrossRefPubMed

35.

Raimundo K, Chang E, Broder MS, Alexander K, Zazzali J, Swigris JJ. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2016;16:2. https://doi.org/10.1186/s12890-015-0165-1.CrossRefPubMedPubMedCentral

36.

Mooney JJ, Raimundo K, Chang E, Broder MS. Hospital cost and length of stay in idiopathic pulmonary fibrosis. J Med Econ. 2017;20(5):518–24. https://doi.org/10.1080/13696998.2017.1282864.CrossRefPubMed

37.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459–66. https://doi.org/10.1164/rccm.201011-1790OC.CrossRefPubMed

38.

Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154(1):97–101.CrossRef

39.

Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am. 2016;42(1):157–76, ix-x. https://doi.org/10.1016/j.rdc.2015.08.004.CrossRefPubMed

40.

Ding J, Chen Z, Feng K. Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. Int J Med Sci. 2013;10(7):903–7. https://doi.org/10.7150/ijms.4972.CrossRefPubMedPubMedCentral

41.

Arcadu A, Moua T. Bronchoscopy assessment of acute respiratory failure in interstitial lung disease. Respirology. 2017;22(2):352–9. https://doi.org/10.1111/resp.12909.CrossRefPubMed

42.

Vianello A, Molena B, Turato C, Braccioni F, Arcaro G, Paladini L, et al. Pirfenidone improves the survival of patients with idiopathic pulmonary fibrosis hospitalized for acute exacerbation. Curr Med Res Opin. 2019;35(7):1187–90. https://doi.org/10.1080/03007995.2019.1565530.CrossRefPubMed

43.

Furuya K, Sakamoto S, Shimizu H, Sekiya M, Kinoshita A, Isshiki T, et al. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respir Med. 2017;126:93–9. https://doi.org/10.1016/j.rmed.2017.03.026.CrossRefPubMed

44.

Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–96. https://doi.org/10.1056/NEJMoa1503326.CrossRefPubMed

45.

Vianello A, Arcaro G, Molena B, Turato C, Braccioni F, Paladini L, et al. High-flow nasal cannula oxygen therapy to treat acute respiratory failure in patients with acute exacerbation of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2019;13:1753466619847130. https://doi.org/10.1177/1753466619847130.CrossRefPubMedPubMedCentral

46.

Yokoyama T, Kondoh Y, Taniguchi H, Kataoka K, Kato K, Nishiyama O, et al. Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49(15):1509–14. https://doi.org/10.2169/internalmedicine.49.3222.CrossRefPubMed

47.

Marchioni A, Tonelli R, Ball L, Fantini R, Castaniere I, Cerri S, et al. Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome? Crit Care. 2018;22(1):80. https://doi.org/10.1186/s13054-018-2002-4.CrossRefPubMedPubMedCentral

48.

Fernandez-Perez ER, Yilmaz M, Jenad H, Daniels CE, Ryu JH, Hubmayr RD, et al. Ventilator settings and outcome of respiratory failure in chronic interstitial lung disease. Chest. 2008;133(5):1113–9. https://doi.org/10.1378/chest.07-1481.CrossRefPubMed

49.

Kulkarni T, Sharma NS, Diaz-Guzman E. Extracorporeal membrane oxygenation in adults: a practical guide for internists. Cleve Clin J Med. 2016;83(5):373–84. https://doi.org/10.3949/ccjm.83a.15021.CrossRefPubMed

50.

Dotan Y, Vaidy A, Shapiro WB, Zhao H, Dass C, Toyoda Y, et al. Effect of acute exacerbation of idiopathic pulmonary fibrosis on lung transplantation outcome. Chest. 2018;154(4):818–26. https://doi.org/10.1016/j.chest.2018.06.027.CrossRefPubMed

51.

Idiopathic Pulmonary Fibrosis Clinical Research N, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77. https://doi.org/10.1056/NEJMoa1113354.CrossRef

52.

Donahoe M, Valentine VG, Chien N, Gibson KF, Raval JS, Saul M, et al. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. PLoS One. 2015;10(6):e0127771. https://doi.org/10.1371/journal.pone.0127771.CrossRefPubMedPubMedCentral

53.

Novelli L, Ruggiero R, De Giacomi F, Biffi A, Faverio P, Bilucaglia L, et al. Corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: a single center experience and literature review. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(4):385–91.PubMed

54.

Morawiec E, Tillie-Leblond I, Pansini V, Salleron J, Remy-Jardin M, Wallaert B. Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses. Eur Respir J. 2011;38(6):1487–9. https://doi.org/10.1183/09031936.00127311.CrossRefPubMed

55.

Fujimoto K, Taniguchi H, Johkoh T, Kondoh Y, Ichikado K, Sumikawa H, et al. Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality. Eur Radiol. 2012;22(1):83–92. https://doi.org/10.1007/s00330-011-2211-6.CrossRefPubMed

56.

Hozumi H, Hasegawa H, Miyashita K, Yasui H, Suzuki Y, Kono M, et al. Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: a propensity score-matched analysis. Respirology. 2019;24(8):792–8. https://doi.org/10.1111/resp.13506.CrossRefPubMed

57.

Naccache JM, Montil M, Cadranel J, Cachanado M, Cottin V, Crestani B, et al. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP). BMC Pulm Med. 2019;19(1):75. https://doi.org/10.1186/s12890-019-0830-x.CrossRefPubMedPubMedCentral

58.

Sakamoto S, Homma S, Miyamoto A, Kurosaki A, Fujii T, Yoshimura K. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49(2):109–15. https://doi.org/10.2169/internalmedicine.49.2359.CrossRefPubMed

59.

Homma S, Sakamoto S, Kawabata M, Kishi K, Tsuboi E, Motoi N, et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med. 2005;44(11):1144–50. https://doi.org/10.2169/internalmedicine.44.1144.CrossRefPubMed

60.

Horita N, Akahane M, Okada Y, Kobayashi Y, Arai T, Amano I, et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2011;50(3):189–95. https://doi.org/10.2169/internalmedicine.50.4327.CrossRefPubMed

61.

Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(1):L3–7. https://doi.org/10.1152/ajplung.90637.2008.CrossRefPubMedPubMedCentral

62.

Oda K, Ishimoto H, Yamada S, Kushima H, Ishii H, Imanaga T, et al. Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2014;15:109. https://doi.org/10.1186/s12931-014-0109-y.CrossRefPubMedPubMedCentral

63.

Sakamoto S, Shimizu H, Isshiki T, Sugino K, Kurosaki A, Homma S. Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a historically controlled study. Respir Investig. 2018;56(2):136–43. https://doi.org/10.1016/j.resinv.2017.10.004.CrossRefPubMed

64.

Tsushima K, Yamaguchi K, Kono Y, Yokoyama T, Kubo K, Matsumura T, et al. Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: a proof of concept study. Pulm Pharmacol Ther. 2014;29(2):233–40. https://doi.org/10.1016/j.pupt.2014.04.008.CrossRefPubMed

65.

Kataoka K, Taniguchi H, Kondoh Y, Nishiyama O, Kimura T, Matsuda T, et al. Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2015;148(2):436–43. https://doi.org/10.1378/chest.14-2746.CrossRefPubMed

66.

Isshiki T, Sakamoto S, Kinoshita A, Sugino K, Kurosaki A, Homma S. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respiration. 2015;89(3):201–7. https://doi.org/10.1159/000369828.CrossRefPubMed

67.

Abe S, Azuma A, Mukae H, Ogura T, Taniguchi H, Bando M, et al. Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation: a multicenter retrospective analysis. Intern Med. 2012;51(12):1487–91. https://doi.org/10.2169/internalmedicine.51.6965.CrossRefPubMed

68.

Oishi K, Mimura-Kimura Y, Miyasho T, Aoe K, Ogata Y, Katayama H, et al. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013;61(1):84–9. https://doi.org/10.1016/j.cyto.2012.08.032.CrossRefPubMed

69.

Abe S, Hayashi H, Seo Y, Matsuda K, Kamio K, Saito Y, et al. Reduction in serum high mobility group box-1 level by polymyxin B-immobilized fiber column in patients with idiopathic pulmonary fibrosis with acute exacerbation. Blood Purif. 2011;32(4):310–6. https://doi.org/10.1159/000330325.CrossRefPubMed

70.

Enomoto N, Mikamo M, Oyama Y, Kono M, Hashimoto D, Fujisawa T, et al. Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulm Med. 2015;15:15. https://doi.org/10.1186/s12890-015-0004-4.CrossRefPubMedPubMedCentral

Title: Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Who to Treat, How to Treat
Authors: Tejaswini Kulkarni
Steven R. Duncan
Publication date: 01-12-2019
Publisher: Springer US
Keyword: Idiopathic Pulmonary Fibrosis
Published in: Current Pulmonology Reports / Issue 4/2019
Electronic ISSN: 2199-2428
DOI: https://doi.org/10.1007/s13665-019-00238-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2019

The Spectrum of Drug-Induced Interstitial Lung Disease

Bronchoscopy: Past, Present, and Future

Hemoptysis: Rethinking Management

Nontuberculous Mycobacteria Infection: Source and Treatment

Photodynamic Therapy and Its Use in Lung Disease

Role of New Imaging Capabilities with MRI and CT in the Evaluation of Bronchiectasis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials